111 related articles for article (PubMed ID: 32789680)
1. PSMA whole-body tumor burden in primary staging and biochemical recurrence of prostate cancer.
Santos A; Mattiolli A; Carvalheira JB; Ferreira U; Camacho M; Silva C; Costa F; Matheus W; Lima M; Etchebehere E
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):493-500. PubMed ID: 32789680
[TBL] [Abstract][Full Text] [Related]
2.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
[TBL] [Abstract][Full Text] [Related]
5. [
Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of whole-body tumor burden with
Brito AET; Mourato FA; de Oliveira RPM; Leal ALG; Filho PJA; de Filho JLL
Ann Nucl Med; 2019 May; 33(5):344-350. PubMed ID: 30746599
[TBL] [Abstract][Full Text] [Related]
7. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-MIP-1404 SPECT/CT for Assessment of Whole-Body Tumor Burden and Treatment Response in Patients With Biochemical Recurrence of Prostate Cancer.
Schmidkonz C; Götz TI; Atzinger A; Ritt P; Prante O; Kuwert T; Bäuerle T; Goebell P; Cordes M
Clin Nucl Med; 2020 Aug; 45(8):e349-e357. PubMed ID: 32558706
[TBL] [Abstract][Full Text] [Related]
9. Correlations between whole body volumetric parameters of
Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
[TBL] [Abstract][Full Text] [Related]
10.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
11. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
12. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using
Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 68Ga-PSMA PET/CT with volumetric parameters for staging of prostate cancer patients.
Aksu A; Karahan Şen NP; Tuna EB; Aslan G; Çapa Kaya G
Nucl Med Commun; 2021 May; 42(5):503-509. PubMed ID: 33560717
[TBL] [Abstract][Full Text] [Related]
14. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
15. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
[TBL] [Abstract][Full Text] [Related]
16. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
18. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
Rauscher I; Maurer T; Souvatzoglou M; Beer AJ; Vag T; Wirtz M; Weirich G; Wester HJ; Gschwend JE; Schwaiger M; Schottelius M; Eiber M
Clin Nucl Med; 2016 Sep; 41(9):e397-402. PubMed ID: 27276206
[TBL] [Abstract][Full Text] [Related]
19. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
20. PSMA SPECT/CT with
Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
